Moderna CEO's statement that existing vaccines will not perform as expected against the new OMICRON stamp. The news that the US authorities, seeking to expand their participation in the global vaccination program, forced Moderna to transfer up to 60% of the vaccine doses produced, proves that the situation with COVID-19 will not calm down for a long time. The fall in Moderna's share price against the backdrop of these two events only shows the fear of buyers about two real facts:
1 - the demand for the vaccine for participation in the mass vaccination program speaks of its already existing efficacy
2 - The CEO's informed opinion (which other companies in the biotech sector lacks) confirms the reality of the problem that Moderna has already begun to work on.
The stock itself is highly speculative, but facts are facts.

$Moderna, Inc.(MRNA)$